p53-expressing oncolytic adenovirus enhances the anti-tumor effect of chemotherapy and radiotherapy

2015 Fiscal Year Final Research Report

• Project/Area Number: 25293323
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Okayama University
• Principal Investigator: Ozaki Toshifumi 岡山大学, 医歯(薬)学総合研究科, 教授 (40294459)
• Co-Investigator(Kenkyū-buntansha): KUNISADA TOSHIYUKI 岡山大学, 医歯(薬)学総合研究科, 准教授 (80346428) ; FUJIWARA TOSHIYOSHI 岡山大学, 医歯(薬)学総合研究科, 教授 (00304303)
• Co-Investigator(Renkei-kenkyūsha): FURUMATSU TAKAYUKI 岡山大学, 大学病院, 助教 (20432651) ; TAKEDA KEN 岡山大学, 医歯(薬)学総合研究科, 助教 (70614923)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: ウイルス治療 / 骨軟部肉腫 / p53 / 化学療法 / 放射線療法

Outline of Final Research Achievements

Despite major advances in the treatment of bone and soft tissue sarcomas, some patients show a poor response to chemotherapy and radiotherapy, leading to a poor prognosis. We recently developed the p53-expressing oncolytic adenovirus, OBP-702. And we confirmed OBP-702 effectively killed human osteosarcoma cells. In the present study, we evaluated the efficacy of combined treatment with OBP-702 and chemotherapy or radiotherapy on human bone and soft tissue sarcoma cells. OBP-702 enhanced the anti-tumor effect of chemotherapy and radiotherapy.

Free Research Field

骨軟部腫瘍